Discovery of novel CDK8 inhibitors using multiple crystal structures in docking-based virtual screening.
暂无分享,去创建一个
Fang Wang | Zhuang Yang | Taijin Wang | Yongguang Zhang | F. Wang | Zhuang Yang | Lijuan Chen | Wei Yan | Taijin Wang | Yongguang Zhang | Wei-Qun Yan | Linhong He | Yuanyuan Zhou | Linhong He | Yuanyuan Zhou | Lijuan Chen
[1] K. Bowman,et al. Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. , 2016, ACS medicinal chemistry letters.
[2] M. Mikuła,et al. CDK8 kinase--An emerging target in targeted cancer therapy. , 2015, Biochimica et biophysica acta.
[3] J. Bajorath,et al. Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.
[4] Branka Jeličić,et al. The two faces of Cdk8, a positive/negative regulator of transcription. , 2014, Biochimie.
[5] Na Li,et al. Cyclin C is a haploinsufficient tumour suppressor , 2014, Nature Cell Biology.
[6] Xiao Yu,et al. Protein Flexibility in Docking-Based Virtual Screening: Discovery of Novel Lymphoid-Specific Tyrosine Phosphatase Inhibitors Using Multiple Crystal Structures , 2015, J. Chem. Inf. Model..
[7] Pablo Tamayo,et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity , 2008, Nature.
[8] Julian Blagg,et al. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19 , 2016, Journal of medicinal chemistry.
[9] Gary Box,et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease , 2015, Nature chemical biology.
[10] Joan W Conaway,et al. The mammalian Mediator complex and its role in transcriptional regulation. , 2005, Trends in biochemical sciences.
[11] Wu Xu,et al. All-atomic molecular dynamic studies of human CDK8: Insight into the A-loop, point mutations and binding with its partner CycC , 2014, Comput. Biol. Chem..
[12] R. Huber,et al. Structure–kinetic relationship study of CDK8/CycC specific compounds , 2013, Proceedings of the National Academy of Sciences.
[13] B. Garcia,et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8 , 2010, Nature.
[14] R. Huber,et al. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. , 2011, Journal of molecular biology.
[15] Philippe Bergeron,et al. Development of a Potent, Specific CDK8 Kinase Inhibitor Which Phenocopies CDK8/19 Knockout Cells. , 2016, ACS medicinal chemistry letters.
[16] Sung-Chul Lim,et al. Roles of cyclin-dependent kinase 8 and β-catenin in the oncogenesis and progression of gastric adenocarcinoma. , 2011, International journal of oncology.
[17] Julian Blagg,et al. Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. , 2016, Journal of medicinal chemistry.
[18] Julian Blagg,et al. Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore. , 2016, Bioorganic & medicinal chemistry letters.
[19] Phil S. Baran,et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities , 2012, Proceedings of the National Academy of Sciences.
[20] S. Armstrong,et al. Mediator Kinase Inhibition Further Activates Super-Enhancer Associated Genes in AML , 2015, Nature.
[21] Shuji Ogino,et al. CDK8 expression in 470 colorectal cancers in relation to β‐catenin activation, other molecular alterations and patient survival , 2010, International journal of cancer.